Table 4 Systemic therapies after LND. Additional systemic therapies are shown. Only therapies after LND and before occurrence of regional recurrence has been recorded
Overall | SaphRes | SaphSpar | p value | ||
|---|---|---|---|---|---|
Interferone | [%] | 17.0 | 21.0 | 10.5 | 0.1773 |
Any chemotherapy | [%] | 20.0 | 17.7 | 23.7 | 0.4709 |
Dacarbazine | [%] | 17.0 | 14.5 | 21.1 | 0.3983 |
Paclitaxel | [%] | 6.0 | 6.5 | 5.3 | 0.8081 |
Cisplatin | [%] | 4.0 | 3.2 | 5.3 | 0.6138 |
Vemurafenib | [%] | 1.0 | 0.0 | 2.6 | 0.1992 |
Sorafenib | [%] | 1.0 | 1.6 | 0.0 | 0.4314 |
Ipilimumab | [%] | 7.0 | 6.5 | 7.9 | 0.7837 |
Vaccination | [%] | 6.0 | 6.5 | 5.3 | 0.8081 |